Drug ingredients were key to Ireland's manufacturing growth in 2013 says CSO

By Gareth Macdonald

- Last updated on GMT

CSO offices in Cork, Ireland
CSO offices in Cork, Ireland

Related tags European union Ireland

Basic pharmaceuticals including APIs became even more important revenue generators for Ireland in 2013 according to new data released by the Central Statistics Office (CSO).

The net selling value of products made and sold by Irish firms in 2013 was €89.9bn ($121.5bn) up 4.6% on the previous year, thanks mainly to the value of basic pharmaceutical products and preparations made in the country growing 7.2% to €29bn.

Drugs and chemicals also contributed a bigger share of revenue according to a CSO spokesman, who told in-Pharmatechnologist.com that: “As a percentage of total industrial production in 2013, pharmaceuticals and chemicals accounted for 44.6%.”

In 2012, revenue from manufacturing in Ireland was €85.9bn with pharmaceuticals and chemicals accounted for 43.7% of all sales.

New entrants drive

The CSO spokesman declined to specify what had driven the drug manufacturing growth, explaining that the PRODCOM survey “collects details of the manufacturing activities and/or industrial services relating to industrial units for the year.

He added that: “Information relates to the sales and or fees earned in relation to all products manufactured in Ireland or outsourced abroad by our enterprises and sold during the year in Ireland or throughout the world.

As the survey reported the Nett Selling Value (NSV) we can only report aggregated values. The values and volumes reported by individual units are subject to confidentiality rules and cannot be disclosed.​”

According to a report​ in the Irish Independent “the rise in value is attributed to a range of factors, including the fact that new entrants were included in the data and that a blockbuster drug came off patent only halfway through the year​.”

The 2013 figures also underline the importance of the pharmaceuticals for Ireland’s manufacturing sector relative to other EU member states where – also according to the survey - 11.7% of industrial revenue comes from drug making.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more